Quest's Focus Dx, Scripps Developing Plavix-Response Test for 3M Integrated Cycler | GenomeWeb

By Ben Butkus

Quest Diagnostics subsidiary Focus Diagnostics is developing a CYP2C19 genotyping test to aid physicians in predicting a patient's response to clopidogrel, sold by Bristol-Myers Squibb under the brand name Plavix, a Quest spokesperson said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.